Pursuant to the provisions of Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you ....
ELITECON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Elitecon International's Board approved its unaudited standalone and consolidated results for Q3 FY26 (Dec 2025) and 9M FY26 on March 7, 2026. Standalone Q3 net sales came in at Rs 50,272.92 lakhs with a profit of Rs 953.88 lakhs, while 9M FY26 net sales surged to Rs 1,20,684.95 lakhs and profit rose to Rs 5,012.02 lakhs (vs Rs 17,709.73 lakhs sales and Rs 1,999.89 lakhs profit in 9M FY25). On a consolidated basis, 9M FY26 net sales jumped to Rs 5,47,688.65 lakhs with a profit of Rs 31,116.69 lakhs, driven by subsidiaries including Sunbridge Agro, Landsmill Agro, Golden Cryo, and overseas units in Dubai and Singapore. The company completed a share subdivision from Rs 10 to Rs 1 face value during the nine months. The company also flagged several material matters: FDA seizure of non-cigarette tobacco inventory and machinery at its Nashik plant (Jan 2026), a pending DGGI GST show cause notice for Oct 2020-Oct 2024, ongoing IBC proceedings filed by Advik Capital at NCLT, and partial completion of subsidiary acquisitions due to a failed QIP and unreleased pledged shares.
Strong topline and profit growth on both standalone and consolidated basis is a positive signal, though year-on-year comparisons are distorted by recent acquisitions and the share subdivision (10:1). Shareholders should watch the FDA tobacco seizure case, the DGGI GST adjudication, and the Advik Capital NCLT matter (next hearing March 20, 2026) as key risk events that could materially affect operations and stock sentiment.